The purpose of the study was to determine the influence of fluvastatin and atorvastatin on platelet aggregation in patients treated with aspirin and plavix after coronary stenting. We hypothezied a positive effect of fluvastatin on platelet aggregation levels.

all patients with stent implantation followed by treatment with aspirin and clopidogrel

routinely treated with acetylsalicylic 100 mg/day

Exclusion Criteria:

acute coronary syndrome

use of a GPIIb/IIIa inhibitor

allergy to acetylsalicylic acid, clopidogrel, statins

elevated liver enzymes (> 3 x norm value)

muscle myopathy

active liver disease

recent gastrointestinal bleeding (< 3 months)

known platelet dysfunction or abnormal platelet count

pregnancy

indication for treatment with non-steroidal drugs

indication for long-term treatment with a drug metabolized by cytochrome p450 3A4 or 2C9

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00465322